P797: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF COMBINATION POZELIMAB AND CEMDISIRAN THERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO SWITCH FROM ECULIZUMAB
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-08-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000970092.68730.83 |
| _version_ | 1797280828556836864 |
|---|---|
| author | Richard Kelly Nicola Houghton Talha Munir Petra Muus Nora Youngs Lisa Aurand Brian Senk Rodrigo Pavani Lorah Perlee Amal Souttou Morag Griffin |
| author_facet | Richard Kelly Nicola Houghton Talha Munir Petra Muus Nora Youngs Lisa Aurand Brian Senk Rodrigo Pavani Lorah Perlee Amal Souttou Morag Griffin |
| author_sort | Richard Kelly |
| collection | DOAJ |
| first_indexed | 2024-03-07T16:46:50Z |
| format | Article |
| id | doaj.art-0619e6938917410e96f0408b6543771a |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T16:46:50Z |
| publishDate | 2023-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-0619e6938917410e96f0408b6543771a2024-03-03T06:25:09ZengWileyHemaSphere2572-92412023-08-017e687308310.1097/01.HS9.0000970092.68730.83202308003-00697P797: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF COMBINATION POZELIMAB AND CEMDISIRAN THERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO SWITCH FROM ECULIZUMABRichard Kelly0Nicola Houghton1Talha Munir2Petra Muus3Nora Youngs4Lisa Aurand5Brian Senk6Rodrigo Pavani7Lorah Perlee8Amal Souttou9Morag Griffin101 St James’s University Hospital, Leeds, United Kingdom1 St James’s University Hospital, Leeds, United Kingdom1 St James’s University Hospital, Leeds, United Kingdom1 St James’s University Hospital, Leeds, United Kingdom1 St James’s University Hospital, Leeds, United Kingdom2 Regeneron Pharmaceuticals, Inc., Tarrytown, United States2 Regeneron Pharmaceuticals, Inc., Tarrytown, United States2 Regeneron Pharmaceuticals, Inc., Tarrytown, United States2 Regeneron Pharmaceuticals, Inc., Tarrytown, United States2 Regeneron Pharmaceuticals, Inc., Tarrytown, United States1 St James’s University Hospital, Leeds, United Kingdomhttp://journals.lww.com/10.1097/01.HS9.0000970092.68730.83 |
| spellingShingle | Richard Kelly Nicola Houghton Talha Munir Petra Muus Nora Youngs Lisa Aurand Brian Senk Rodrigo Pavani Lorah Perlee Amal Souttou Morag Griffin P797: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF COMBINATION POZELIMAB AND CEMDISIRAN THERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO SWITCH FROM ECULIZUMAB HemaSphere |
| title | P797: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF COMBINATION POZELIMAB AND CEMDISIRAN THERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO SWITCH FROM ECULIZUMAB |
| title_full | P797: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF COMBINATION POZELIMAB AND CEMDISIRAN THERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO SWITCH FROM ECULIZUMAB |
| title_fullStr | P797: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF COMBINATION POZELIMAB AND CEMDISIRAN THERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO SWITCH FROM ECULIZUMAB |
| title_full_unstemmed | P797: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF COMBINATION POZELIMAB AND CEMDISIRAN THERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO SWITCH FROM ECULIZUMAB |
| title_short | P797: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF COMBINATION POZELIMAB AND CEMDISIRAN THERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO SWITCH FROM ECULIZUMAB |
| title_sort | p797 a phase 2 open label study evaluating the safety and efficacy of combination pozelimab and cemdisiran therapy in patients with paroxysmal nocturnal hemoglobinuria who switch from eculizumab |
| url | http://journals.lww.com/10.1097/01.HS9.0000970092.68730.83 |
| work_keys_str_mv | AT richardkelly p797aphase2openlabelstudyevaluatingthesafetyandefficacyofcombinationpozelimabandcemdisirantherapyinpatientswithparoxysmalnocturnalhemoglobinuriawhoswitchfromeculizumab AT nicolahoughton p797aphase2openlabelstudyevaluatingthesafetyandefficacyofcombinationpozelimabandcemdisirantherapyinpatientswithparoxysmalnocturnalhemoglobinuriawhoswitchfromeculizumab AT talhamunir p797aphase2openlabelstudyevaluatingthesafetyandefficacyofcombinationpozelimabandcemdisirantherapyinpatientswithparoxysmalnocturnalhemoglobinuriawhoswitchfromeculizumab AT petramuus p797aphase2openlabelstudyevaluatingthesafetyandefficacyofcombinationpozelimabandcemdisirantherapyinpatientswithparoxysmalnocturnalhemoglobinuriawhoswitchfromeculizumab AT norayoungs p797aphase2openlabelstudyevaluatingthesafetyandefficacyofcombinationpozelimabandcemdisirantherapyinpatientswithparoxysmalnocturnalhemoglobinuriawhoswitchfromeculizumab AT lisaaurand p797aphase2openlabelstudyevaluatingthesafetyandefficacyofcombinationpozelimabandcemdisirantherapyinpatientswithparoxysmalnocturnalhemoglobinuriawhoswitchfromeculizumab AT briansenk p797aphase2openlabelstudyevaluatingthesafetyandefficacyofcombinationpozelimabandcemdisirantherapyinpatientswithparoxysmalnocturnalhemoglobinuriawhoswitchfromeculizumab AT rodrigopavani p797aphase2openlabelstudyevaluatingthesafetyandefficacyofcombinationpozelimabandcemdisirantherapyinpatientswithparoxysmalnocturnalhemoglobinuriawhoswitchfromeculizumab AT lorahperlee p797aphase2openlabelstudyevaluatingthesafetyandefficacyofcombinationpozelimabandcemdisirantherapyinpatientswithparoxysmalnocturnalhemoglobinuriawhoswitchfromeculizumab AT amalsouttou p797aphase2openlabelstudyevaluatingthesafetyandefficacyofcombinationpozelimabandcemdisirantherapyinpatientswithparoxysmalnocturnalhemoglobinuriawhoswitchfromeculizumab AT moraggriffin p797aphase2openlabelstudyevaluatingthesafetyandefficacyofcombinationpozelimabandcemdisirantherapyinpatientswithparoxysmalnocturnalhemoglobinuriawhoswitchfromeculizumab |